skip to main content
Idioma:
Resultados 1 2 3 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors
738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors

Olson, Daniel J ; Dumbrava, Ecaterina ; Saibil, Sam ; Gutierez, Martin ; Iqbal, Syma ; Sohal, Davendra ; Apostolopoulou, Maria ; Moss, Kara ; Adib, Deyaa ; Schlechter, Benjamin

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A831-A831 [Periódico revisado por pares]

London: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
2
654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

Olson, Daniel J ; Dumbrava, Ecaterina ; George, Mridula ; Saibil, Sam ; Butler, Marcus ; Giordano, Antonio ; Pieke, Brooke ; Gavriliuc, Miriam ; Lichtenstein, Emily ; Geisberger, Jill ; Apostolopoulou, Maria ; Moss, Kara ; Kirkwood, D’Arcy ; Dang, Salina ; Adib, Deyaa ; Schlechter, Benjamin

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A745-A745 [Periódico revisado por pares]

London: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
3
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Morschhauser, Franck ; Tilly, Hervé ; Chaidos, Aristeidis ; McKay, Pamela ; Phillips, Tycel ; Assouline, Sarit ; Batlevi, Connie Lee ; Campbell, Phillip ; Ribrag, Vincent ; Damaj, Gandhi Laurent ; Dickinson, Michael ; Jurczak, Wojciech ; Kazmierczak, Maciej ; Opat, Stephen ; Radford, John ; Schmitt, Anna ; Yang, Jay ; Whalen, Jennifer ; Agarwal, Shefali ; Adib, Deyaa ; Salles, Gilles

The lancet oncology, 2020-11, Vol.21 (11), p.1433-1442 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials
Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

Proudman, David ; Nellesen, Dave ; Gupta, Deepshekhar ; Adib, Deyaa ; Yang, Jay ; Keith, Michael ; Mamlouk, Khalid

Blood, 2020-11, Vol.136 (Supplement 1), p.16-16 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib

Proudman, David ; Nellesen, Dave ; Gupta, Deepshekhar ; Adib, Deyaa ; Yang, Jay ; Mamlouk, Khalid

Advances in therapy, 2022-04, Vol.39 (4), p.1678-1696 [Periódico revisado por pares]

Cheshire: Springer Healthcare

Texto completo disponível

Citações Citado por
6
Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat
Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat
Material Type:
Artigo 		Adicionar ao Meu Espaço

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

Dave, Sandeep S. ; Happ, Lanie ; Yasso, Christopher ; Salles, Gilles ; Batlevi, Connie Lee ; Phillips, Tycel ; Yang, Jay ; Adib, Deyaa ; Michaud, Neil R. ; Morschhauser, Franck

Blood, 2021-11, Vol.138 (Supplement 1), p.1183-1183 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

Schlechter, Benjamin L. ; Olson, Daniel ; George, Mridula Annette ; Saibil, Sam ; Giordano, Antonio ; Bouvier, Riemke ; Gavriliuc, Miriam ; Pieke, Brooke ; Gruber, Kelly ; Lichtenstein, Emily ; Apostolopoulou, Maria ; Moss, Kara M. ; Ternus, Nathan ; Adib, Deyaa R ; Dumbrava, Ecaterina Elena

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2519-2519 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors
A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors

Schlechter, Benjamin L. ; Olson, Daniel ; Saibil, Samuel ; George, Mridula Annette ; Gruber, Kelly ; Bouvier, Riemke ; Pieke, Brooke ; Geisburger, Jill ; Moss, Kara M. ; Ternus, Nathan ; Adib, Deyaa R ; Dumbrava, Ecaterina Elena

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS816-TPS816 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Batlevi, Connie Lee ; Park, Steven I. ; Nastoupil, Loretta ; Phillips, Tycel ; Amengual, Jennifer E. ; Andorsky, David ; Campbell, Philip ; McKay, Pamela ; Pagel, John M. ; Leonard, John P. ; Yang, Jay ; O'Connor, Heather ; Hamlett, Anthony ; Adib, Deyaa ; Morschhauser, Franck

Blood, 2021-11, Vol.138 (Supplement 1), p.2207-2207 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Abida, Wassim ; Bradley, Thomas Paul ; Rezazadeh, Arash ; Karsh, Lawrence Ivan ; Ross, Ashley ; Saltzstein, Daniel ; Argon, Evren Kocabas ; Hamlett, Anthony ; Tang, Jeanie ; Adib, Deyaa

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS255-TPS255 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (28)
  2. Anais de Congresso  (2)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2015  (2)
  2. 2015Até2016  (7)
  3. 2017Até2018  (3)
  4. 2019Até2021  (8)
  5. Após 2021  (11)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.